undamentalytics Newsletter
Sign in

Alterity Therapeutics LTD (ATHE) stock

Add to watchlist

Add holding +

NASDAQ: ATHE Nasdaq Biotechnology

Alterity Therapeutics LTD is a US-listed company in the biotechnology industry. Its financial year ends in June.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: data-quality checks not passed.

Price vs value

Under review: data-quality checks not passed. We'll show the comparison once resolved.

Alterity Therapeutics LTD valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders1 buying, 0 selling1 purchase and 0 sales by directors and officers, last 12 monthsInsider trades
  • Funds14 adding, 0 cuttingOf 1 active managers that changed their stake, 1 added; quarter to June 30, 2026Fund buyers and sellers

The Fundamentalytics view

Current signal Revenue growth accelerating: TTM revenue growth rose to 56.1% (+60.1pp vs the prior quarter).

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Fast growth. Revenue grew 56.1% over the last 12 months.
  • Growth speeding up. The growth rate is 60.1 points higher than a quarter earlier.
  • Shrinking share count. Diluted shares fell 96.7% in a year, so each share owns more of the business.
  • Net cash. Cash exceeds long-term debt by $0.0bn.

Things to watch

  • Burning cash. Free cash flow was -3135.4% of revenue over the last 12 months.

Price chart

  • 1 day-3.2%
  • 1 week+0.5%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

EPS (TTM, diluted)
$-0.91

Growth

Share count change
−96.7%

Cash

Free cash flow (TTM)
-$15.3M

News & updates

Updated November 2, 2026

Company announcements, filed results and changes that matter to shareholders.

No recent updates are available for ATHE from the sources we follow. See filings →

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Alterity Therapeutics LTD valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: data-quality checks not passed.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

No analyst estimates are published for Alterity Therapeutics LTD: too few analysts cover it.

Analyst recommendations

4 analysts, Nov 2026
Buy4100%
Hold00%
Sell00%

Monthly trend

  1. Nov 2026134
  2. Oct 2026134

Counts of recommendations published by analysts covering Alterity Therapeutics LTD, by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
0.2%
of tradable shares
Days to cover
1.73
at average volume
Short interest, 1 month
+50%
to October 15, 2026
Held by institutions
2%
of shares
Held by insiders
0.0%
of shares
Employees
11
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Recent prices are available. Older price history and the statistics that need it are being loaded in the background.

Price behaviour

52-week range
Not enough history
From 52-week high
—
vs 50-day average
—
vs 200-day average
—
Volatility (1 year)
—
Beta vs S&P 500
—

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Fundamentals

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 20-F. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2016 Jun 2016 2017 Jun 2017 2018 Jun 2018
Income
Revenue 0 0 0
Net income −6 −6 −6
Growth (year on year)
Revenue — −3.9% +56.1%
Margins
Net margin <−999% <−999% <−999%
Free-cash-flow margin <−999% <−999% <−999%
Cash flow
Cash from operations −5 −4 −5
Capital spending 0 0 0
Free cash flow −5 −4 −5
Balance sheet
Cash 21 17 11
Total debt 0 0 0
Net debt (negative = net cash) −21 −17 −11
Diluted shares 44m 44m 44m

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 2 checks passed · June 30, 2026
What it owns · $32m
Short-term assets $32mLonger-term assets $0m
What it owes, and who funded it · $32m
Short-term liabilities $2mLonger-term liabilities $0mShareholders' equity $30m
  • Short-term assets cover short-term liabilities $32m of assets due within a year against $2m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $32m short-term assets against $95,628 of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Alterity Therapeutics LTD's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
−96.7%
year over year

Competitors: side by side with peers

Closest by revenue in biotechnology
Last 12 months unless stated ATHE CLDX CLNN IBIO LSTA AIM Median
Revenue, last 12 months $155962 $158000 $197000 $100000 $100000 $95000 $55m
Revenue growth, last 12 months 56.1% −97.3% −31.1% −75.0% −90.7% −21.5% 12.7%
Revenue growth, 3-year average — −63.5% −36.9% −62.4% — −17.3% 13.7%
Revenue growth, latest quarter — −97.0% 233.3% −100.0% −100.0% 4.0% 10.2%
Gross margin — — 70.1% 59.9% 7.7% −968.5% 82.9%
Operating margin — <−999% <−999% <−999% <−999% <−999% −189.4%
Operating margin, 3-year average — <−999% <−999% <−999% <−999% <−999% −363.5%
Net margin <−999% <−999% <−999% <−999% <−999% <−999% −172.8%
Cash from operations / revenue <−999% <−999% <−999% <−999% <−999% <−999% −168.8%
Free-cash-flow margin <−999% <−999% <−999% <−999% <−999% <−999% −168.1%
Free-cash-flow margin, 3-year average — <−999% <−999% <−999% <−999% <−999% −310.0%
Stock pay / revenue — >999% >999% >999% >999% 0.0% 20.0%
Change in share count −96.7% 4.7% 35.4% 13.9% 5.1% 49.8% 8.1%

Median of all 185 companies we cover in biotechnology. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Who owns it

Funds buying and selling
Reported value
$2.1M
Institutions reporting
22
Shares held vs prior quarter
▲ 23.0%
Positions opened / closed
7 / 0

Top buyers and sellers, Q2 2026: 14 institutions bought and 0 sold ; the biggest buyer was Greenleaf Trust (+30K shares) . See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Twin Lakes Capital Management, LLC $747,815 139K 35.3% 0.0%
Morgan Stanley $338,660 63K 16.0% ▲ 8.0%
Greenleaf Trust $332,940 62K 15.7% ▲ 93.8%
Hb Wealth Management, LLC $313,930 58K 14.8% 0.0%
Citadel Advisors LLC $201,896 38K 9.5% ▲ 87.3%
HRT Financial LP $92,000 17K 4.3% New
BNP Paribas Financial Markets $54,983 10K 2.6% ▲ 50.4%
Gamma Investing LLC $12,399 2K 0.6% ▲ 24.4%
Rhumbline Advisers $10,786 2K 0.5% ▲ 2.0%
Acadian Asset Management LLC $10,000 2K 0.5% 0.0%
Providence Capital Advisors, LLC $1,074 0K 0.1% New
Integrated Wealth Concepts LLC $392 0K 0.0% New

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Alterity Therapeutics LTD's complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $23,810 1 trade by 1 insider, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $23,810 net buying
Insider Date Trade Shares Price Value
Marks Peter Ashley Director August 31, 2026 Buy 47,620 $0.50 $23,810

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Recent SEC filings

Data status

When each part of this page on Alterity Therapeutics LTD was last updated.

DataLast updatedSource
Share priceExchange closing prices
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Alterity Therapeutics LTD in brief

What does Alterity Therapeutics LTD do?
Alterity Therapeutics LTD is a US-listed company in the biotechnology industry. Its financial year ends in June.
What is Alterity Therapeutics LTD's stock ticker?
Alterity Therapeutics LTD trades under the ticker ATHE on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
Who are Alterity Therapeutics LTD's largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Twin Lakes Capital Management, LLC, Morgan Stanley and Greenleaf Trust. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Who are Alterity Therapeutics LTD's competitors?
In our Biotechnology peer group, the companies closest to Alterity Therapeutics LTD are Celldex Therapeutics, Inc., Clene Inc., Ibio, Inc., Lisata Therapeutics, Inc. and AIM Immunotech Inc. The side-by-side comparison below sets their revenue, margins and growth against Alterity Therapeutics LTD's.
Are insiders buying or selling Alterity Therapeutics LTD stock?
Over the last 12 months, Alterity Therapeutics LTD's directors and officers reported 1 open-market purchases and 0 sales on Form 4. The insider trading page charts every trade.